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Among the many regulatory steps in brain development is the process of elimination of differentiating neurons at certain stages 
of maturation through an intrinsic suicide program now widely known as apoptosis. Apoptosis may thus describe a cell death 
pathway utilized by many developing cells in the nervous system, but may also be activated as a consequence of acute or chronic 
pathological impulses. Such pathological impulses may include brain injury, cerebral hypoxia-ischemia and the potentials of 
selected drugs such as N-methyl D-aspartate (NMDA) receptor antagonists, GABA mimetics and ethanol. In recent years, there 
has been a great interest in mechanisms of cell death in the nervous system and apoptotic cell death has been implicated in many 
neurodegenerative diseases such as Alzheimer’s disease, amiotrophic lateral sclerosis, Parkinson’s disease and other central 
and peripheral nervous system disorders. Recent findings have evaluated the contribution of programmed cell death and specific 
gene products involved in each of these cases. A deeper understanding of these processes may lead to the discovery of strategies 
for slowing, reducing or arresting neuronal and glial cell death induced by injury, aging or disease.
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INTRODUCTION 
Massive cell death characterizes the ontogeny and turnover of 
virtually all mammalian tissues and has been identified even 
among plants and bacteria. Spontaneous cell death as a phy-
siological event has been described as soon as histologic stains 
became available. First Flemming in 1885, while studying 
ovarian follicles in mammals, and later Strobe in 1892 while 
studying breast cancer, observed regressing cells at a stage 
of, what we would now call, apoptosis (1,2). They named the 
process “chromatolyis”, referring to the fact that the broken 
up nucleus ultimately disappears. In 1914 Ludwig Gräper 
published a paper entitled “A new point of view regarding 
elimination of cells” (3). In 1934, V. Hamburger described 
significant hypoplasia in dorsal root ganglia (DGR) and lateral 
motor columns, following the extirpation of limb buds in chick 
embryos (4). In the early 1940s, Rita Levi-Montalcini repeated 
Hamburger’s experiment and suggested that the hypoplasia 
might result from the death of young differentiated neurons. 
In a joint reinvestigation published in 1949, large numbers of 
degenerating neurons were described in brachial DRG, fol-
lowing wing bud extirpations (5). In the cervical and thoracic 
DRG of the same embryos, Levi-Montalcini observed massive 
neuronal death, which had not been affected by the operation. 
This in fact marked the discovery of naturally occurring cell 
death in the nervous system. The German anatomists M. Ernst 
and A. Glucksmann also deserve credit for the discovery of 
widespread cell death in embryonic nervous tissues (6). In 
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1972 Kerr and colleagues introduced the term “apoptosis” 
and defined the phenomenon in terms of its ultrastructural 
appearance (7). Although the main focus of their work was on 
non-neuronal tissue, they cited a single example of neuronal 
apoptosis, namely physiological cell death, a suicidal process 
by which redundant or unsuccessful neurons are eliminated 
from the developing brain (7,8). Several years earlier, however, 
before the term “apoptosis” was introduced, Sabatini et al (9), 
and later Levi-Montalcini et al (10), in sympathetic ganglion 
neurons of nerve growth factor (NGF)-deprived animals, 
described ultrastructural changes, remarkably similar to those 
provided later by Kerr and Wyllie. 
CELL DEATH DURING THE DEVELOPMENT OF 
THE NERVOUS SYSTEM
Among the many regulatory steps in brain development, and 
probably one of the most intensely studied in the past two 
decades, is the process of elimination of differentiating neu-
rons at certain stages of maturation known to occur through 
an intrinsic suicide program now widely known as apoptosis. 
Although “apoptosis” is by far the most extensively used and 
often “misused” term to describe examples of genetically re-
gulated cell death processes, perhaps it is best to use the term 
“physiological” or “programmed” cell death (PCD) to describe 
the spatially and temporally reproducible and ordered death of 
cells during embryonic, fetal and early postnatal development. 
We intend to use “apoptosis” in a broader aspect to describe in 
addition death processes induced by pathophysiological stimuli 
during development as well as in adulthood. Apoptosis may 
thus describe a cell death pathway utilized by many, if not 
all, developing cells in the nervous system, but may also be 
activated at the same time as a consequence of acute or chronic 
pathological impulse (11-13). For detailed discussion on the 
controversial and sometimes confusing issues surrounding the 
use of terminologies see references 2,14-19.
In virtually all neuronal populations cell numbers are sub-
stantially greater at early development stages than in maturity 
and the development of the nervous system requires the selec-
tive elimination of a vast number of neurons and glia. Another 
fundamental principle of brain development is the removal 
of early phylogenetic patterns of neuronal organization. For 
example neurons generated early in the development of the 
neocortex are situated in a transient zone known as “cortical 
subplate”. These neurons interconnect with layer I neurons and 
participate in important cell to cell interactions with migrating 
neurons, and also with incoming afferent and efferent projec-
tions. This zone disappears during the course of neurogenesis 
by activating a process of PCD. According to studies in the 
human telencephalon two distinct types of PCD have been 
observed: embryonic, which is synchronous with proliferation 
and migration of neuronal cells, and fetal, which coincides 
with differentiation and synaptogenesis (20). 
Neuronal PCD has been described virtually everywhere in 
the developing nervous system and across species from fish to 
humans (11,21). Although the magnitude of cell death varies 
depending on the specific brain region and postnatal period 
(22), generally 50% of the cell population in the central and 
peripheral nervous systems will be eventually eliminated until 
animals reach maturity. For example, on postnatal day 8 (P8) 
various cortical regions of the rat and mouse brain undergo 
substantial PCD accounting in some layers of the cingulate, 
frontal and parietal cortex for more than 1% of the total cell 
population (22,23). By P21 virtually no cortical PCD has been 
detected. In the cerebellum, however, a number of cells in the 
granule cell layer and white matter exhibit morphological and 
immunohistochemical features consistent with PCD at P21 
(Dikranian et al, unpublished data). In the visual system, more 
than half of neuronal projections from the retina to other visual 
structures are also lost during development. The deletion of up 
to 50% of motoneurons is a normal feature of the developing 
spinal cord too. Moreover, PCD involves not only projection 
neurons innervating skeletal muscles and those of the dorsal 
root ganglia, but also intrinsic interneurons (11,24).
While it has been accepted that large-scale neuronal death is 
a regular feature of the developing vertebrate nervous system, 
much less attention has been given to glial cell apoptosis. 
However Barres et al (25) have shown that about 50% of 
newly formed oligodendrocytes normally die in the developing 
rat optic nerve. During the first and second postnatal week 
Schwann cells of the developing chick embryo spinal cord also 
die in large numbers (26). Krueger et al (27) reported evidence 
(including electron microscopy) for massive (50%) astrocytic 
PCD in the developing rat cerebella during the first and second 
week of development. In addition, about 2% of apoptotic cells 
belong to the oligodendrocyte lineage (27). These findings 
suggest that naturally occurring glial cell death can be just as 
substantial as naturally occurring neuronal cell death. They 
represent also a major advance in our understanding of cell 
elimination in the developing nervous system. Finally, these 
data suggest that as axon number regulates the survival of 
myelinating glial cells (25,26), the normal PCD of these 
cells reflects a competition for limited amounts of axon-
derived growth factors (11). Therefore, just as neuronal PCD 
adjusts the number of neurons, PCD in Schwann cells and 
oligodendrocytes adjusts the glial cell number to the number 
of axons that require myelination. 
Current theories about the regulation of neuronal survival 
hold that most, if not all, neurons in the mammalian nervous 
system are dependent on specific growth factors at certain de-
velopmental stages (11,21,28-30). The experimental evidence 
gathered so far strongly suggests that developing neurons are 
initially overproduced and then later compete for limited amo-
unts of population-specific and target-derived trophic factors. 
Those that fail to do so undergo orderly cell suicide. Survival 
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dependence during development is thought to be most acute ar-
ound the time axons reach their target fields (synaptogenesis), 
the principal source of growth factors. PCD mostly affects rela-
tively mature neurons that have either established connections 
with afferent or efferent targets, or are about to establish them 
(11,31). Deprivation of NGF results in apoptotic cell death of 
virtually all neurons in the peripheral nervous system which 
express its signaling receptor (TrkA). Target deprivation by 
axotomy during the perinatal period also results in massive cell 
death in all populations of neurons presumably due to interrup-
tion of supply of known and as yet unknown growth/trophic 
factors. Of interest is the fact that early spinal motor neuron 
PCD may be determined either by intrinsic programs or local 
factors within the spinal cord, whereas later stages of motor 
neuron death may be dominated by trophic factor influence 
related to interaction with the target muscle (11). While most 
sensory neurons require nerve growth factor (NGF) for their 
survival, other populations require different neurotrophins such 
as neurotrophin (NT)-3, NT-4/5, brain-derived neurotrophic 
factor (BDNF) and glial-derived neurotrophic factor (GDNF). 
For more information on the diverse role of neurotrophins and 
their receptors see references 11,32-35 as well as Volume 10 
(1999) of this journal dedicated to NGF and the 90th anniver-
sary of Dr Rita Levi-Montalcini.
There are also other key regulatory molecules that contri-
bute to different stages of PCD and many of them are being 
used lately as specific diagnostic hallmarks. Cytochrome C 
release from mitochondria and subsequent activities of Apaf-1, 
caspase-9 and caspase-3 have been shown to play a critical role 
in cell elimination during neurogenesis (21,36-38). Caspases 
are a family of cysteine proteases that have been identified as 
key regulators and effectors of apoptotic response in a variety 
of species. Following their activation by a specific signal, 
either through cells surface receptors or through intracellular 
signaling pathways, caspases act concertedly in a cascade 
cleaving a number of proteins, followed by cell disassembly 
and destruction (39). Animals deficient in any of these proteins 
exhibit dramatic neural pathology due to supernumerary 
neuronal progenitor cells. Complementary to these findings, 
Bcl-2 family members have been shown to significantly affect 
the death of postmitotic neuroins in response to trophic factor 
withdrawal or to the addition of apoptotic stimuli (11,28). 
Bax and Bcl-2 have been shown to respectively promote 
and prevent cell death in response to the absence of trophic 
stimulation (40). In a comprehensive study on the developing 
rat brain Mooney and Miller (41) reported that the timing of 
the subsequent expression and ratio of different members of 
Bcl family of proteins and caspase-3 elevation remarkably 
coincided with episodes of developmental cell death. The 
survival of DRG neurons is dependent on the availability of 
NGF for a transient period early in development after which 
these neurons become independent of NGF and survival seems 
to occur via control of the relative levels of expression of 
members of the bcl-2 gene family (42).
APOPTOTIC CELL DEATH INDUCED BY VARIOUS STIMULI
Traumatic brain injury: head trauma 
Children younger than 6 years of age sustain traumatic brain 
injury more frequently than any other age group. Clinical ob-
servations suggest that age decidedly influences morbidity and 
mortality after head injury in children, with those less than 4 
years of age developing worst outcomes (43-45). Brain dama-
ge resulting from mechanical trauma can be classified into 
primary damage occurring shortly after impact, and secondary 
or delayed damage, which may appear several hours or even 
days later (46). It has been recently found that concussive 
head trauma in infant rats can trigger both excitotoxic and 
apoptotic cell death process (46-48). These two cell processes 
can be distinguished from one another quite readily by several 
criteria that were developed in a separate study where ultra-
structural evaluation of the degenerative process proved to be 
of strategic value for determining the specific nature of cell 
death (16,49). Excitotoxic cell death occurs only at the local 
side of concussive impact and transpires rapidly in a 4 hour 
period. Apoptotic cell death process occurs in a disseminated 
manner and evolves on a more delayed schedule over 6 to 24 
hour period and at more distant sites. It affects substantially 
larger number of neurons. Ultrastructurally, the sequence and 
types of morphological changes that characterize excitotoxic 
cell death are strikingly different from the sequence and types 
of changes that characterize apoptotic cell death (49). The 
two processes could be readily distinguished also by their 
response to treatment. N-methyl D-aspartate (NMDA) glu-
tamate receptor antagonists protected against the excitotoxic 
cell death process (47) but exacerbated the apoptotic cell 
death process (48). Activation of caspase-3 appears also to 
play a role (50). Although apoptosis may have contribution 
to post-traumatic deficits, excitotoxic cell death is considered 
to have a primary role (18). Importantly, apoptotic damage 
shows a clear-cut dependency from age in that the younger 
animals (3-14 postnatal days) demonstrate increased vulne-
rability compared to 30-day old animals where virtually no 
apoptotic lesions are detected after the same amount of impact 
force. It raises also the intriguing question for prevailance of 
an apoptotic cell death process after traumatic injury in the 
developing CNS versus the prevailance of a non-apoptotic 
cell death process in the adult CNS (46). The above findings 
may have important implications for the clinical management 
of pediatric head trauma in that apoptotic cell death is by far 
the dominant cell mechanism contributing to the deletion of 
neurons and anti-apoptotic therapy in such cases may prove to 
be beneficial. It questions also the practice of use of ketamine 
(a proven NMDA antagonist) during the stabilization period 
immediately following head trauma (46). On the other hand, 
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the delayed nature of apoptotic neurodegeneration following 
head trauma suggests that there may be a wide time window 
for therapeutic intervention. 
Traumatic brain injury: spinal cord trauma.
Apoptotic cells have been identified by immunostaining for 
activated caspase-3 and terminal deoxynucleotidyltransferase-
mediated dUTP-biotin nick-end labeling (TUNEL) in neurons 
and oligodendrocytes in adult mice after spinal cord contusion 
(51). It has also been suggested that caspase protease activities 
may be involved in delayed neuronal and glial cell apoptosis 
and this increased activity can be reduced by specific inhibitors. 
However, there are also arguments that such a therapeutic 
stimulus may not be effective in improving functional and 
histopathological outcomes following spinal cord injury. 
Ozawa et al (52) documented no significant differences in the 
BBB locomotor scores and contusion volumes between animals 
receiving specific caspase inhibitors and animals receiving 
vehicle alone. Further studies including electron microscopic 
observation of characteristic features of apoptosis suggested 
that peroxynitrite is capable of inducing neuronal apoptosis 
indicating its role especially in secondary spinal cord lesions 
(53). The study suggests that removal of peroxynitrite should 
be considered as a therapeutic approach. Similar to cortical 
neurons, it has been suggested that motoneurons, which die 
following neonatal nerve injury do so through an excitotoxic 
mechanism. Lawson and Lowrie (54), based on quantitative 
analysis and TUNEL (later proven to be a non-selective 
apoptosis marker) after peripheral nerve injury, discussed the 
possibility that excitotoxicity induces motoneuron death by 
apoptosis. They concluded that all motoneuronal death induced 
during the first 12 days after injury occurs by apoptosis, the 
active process being recognizable only for 2 hours. Treatment 
with a NMDA receptor antagonist has reduced the level of cell 
death. However, ultrastructural data demonstrating neuronal 
cells with features characteristic for apoptosis have not been 
presented to verify the nature of the cell death process. 
Hypoxia/ischemia (HI)
The results of morphological, histochemical, and molecular 
studies indicate that in neonatal animal models apoptotic 
mechanisms may account for neuronal death after cerebral 
HI (55-59). A human study demonstrated evidence for 
apoptotic forms of cell death after hypoxic injury, similar 
to those found in brains from stillbirths (60). In addition 
in vitro evidence indicated to an increased susceptibility 
to apoptosis in immature cortical neurons (61). Nakadjima 
et al (56) provided a detailed light microscopic (cells with 
activated caspase-3) and also electron microscopic data for 
a contribution of apoptotic cell death process to the post-
ischemic lesions in a P7 in vivo rat model. Western blot 
analysis showed that activation of caspase-3 protein persists 
for a protracted period after HI injury, suggesting an extended 
therapeutic window in which caspase inhibitors may reduce or 
prevent brain damage after neonatal asphyxia. These findings 
are consistent with other studies showing a delayed caspase-
3 activation and neuroprotection with caspase-3 inhibitors 
(62). Olney et al (59) induced HI (by means of carotid artery 
ligation) in a 7 day old infant rat CNS and found that it caused 
a primary wave of excitotoxic degeneration that transpired 
in 4 hours and destroyed retinal neurons and cells in several 
brain regions on the ipsilateral side. This was followed by 
a delayed wave of apoptotic neurodegeneration (confirmed 
by electron microscopy) within 16-24 hours and affected 
in addition specific contralateral brain regions such as the 
lateral geniculate nucleus and superior colliculus, areas that 
are heavily innervated by retinal ganglion cells destroyed by 
the excitotoxic process. These data imply that when HI occurs 
during synaptogenesis, it can destroy various developing 
neurons both by excitotoxic and apoptotic cell death process 
(55,59). However, the primary and direct effect is excitotoxic 
and mediated by the excessive activation of glutamate recep-
tors leading to the destruction of neurons (59). Loss of these 
neurons causes deafferentation-mediated apoptotic cell death 
at synaptic targets.
In the adult mammalian brain apoptotic cell death in HI 
has been suggested by several research groups. In 1993 Mac-
Manus et al (63) and in 1994 Kihara et al (64), mainly on the 
basis of evidence from DNA laddering, concluded that there 
is an apoptotic component in the selective neuronal death 
following global ischemia in rat and gerbil brain. Later it was 
shown that delayed neuronal death after transient cerebral 
ischemia may be mediated, in part, by the induction of apop-
tosis-regulatory gene products (62). At 8-72 hour interval 
after ischemia, caspase-3 mRNA and protein were induced 
in the hippocampus and caudate-putamen accompanied by 
increased caspase-3-like protease activity in degenerating 
CA1 neurons. Double-label experiments have detected DNA 
fragmentation in the majority of neurons that overexpressed 
caspase-3. Application of Z-DEVD-FMK, a caspase-3 inhibi-
tor, decreased caspase-3 activity and significantly reduced cell 
death and DNA fragmentation. Similar data were reported in 
the adult mouse brain after temporary middle cerebral artery 
occlusion (65). Caspase-like enzyme activity was elevated in 
brain homogenate shortly after reperfusion and reached a peak 
within 30 to 60 min. Activated caspase-3 immunoreactivity 
became prominent within the middle cerebral artery territory 
at the time of reperfusion and 1-12 hours later. Although no 
electron microscopic evidence for apoptotic morphology was 
presented and DNA laddering and TUNEL were the only 
reference standards, both groups pointed to the existence of a 
time-dependent evolution of the ischemic injury characterized 
by the close correspondence between caspase-like enzyme 
activation and an associated increase in activated caspase-3 
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immunoreactivity. On the other hand, it has been shown that 
other cysteine proteases such as calpain and cathepsin may also 
have a role in delayed ischemic neuronal cell death that is not 
represented by morphological features of apoptosis (66,87). 
Given the fact that caspase-3 and calpain share common sub-
strates in neurons, and calpains appear to be involved in the 
activation of caspase-3 in the immature CNS (67), a mutual 
communication during the execution of the cell death process 
after ischemia has been predicted. 
The effect of perinatal asphyxia in the spinal cord in the 
neonatal animals has also been investigated (68). A substantial 
increase in TUNEL and caspase-3 positive cells identified as 
microglia and oligodendrocytes has been established in laminae 
I-III of the lumbar spinal cord of rats at different postnatal days 
following ischemia. In the adult rat, the association of motor 
neuron cell death with activation of caspases after transient 
ischemia of the spinal cord was reported (69).
In conclusion, despite emerging data for a possible con-
tribution of an apoptotic mechanism of cell death in selected 
brain regions after ischemic injury in the adult CNS, it appears 
that post HI apoptosis may play a more extensive role in the 
neonatal mammalian brain. 
Adrenal hormones and neuronal cell survival
Searching the literature for evidence of apoptotic neuro-
degeneration in the adult mammalian CNS, the only well 
characterized example was found in a paper published by 
Sloviter et al in 1993 (70). The authors induced degeneration of 
hippocampal granule neurons in the adult rat brain by surgical 
removal of the adrenal glands. The morphological (including 
electron microscopy) features of this process were virtually 
identical to those classically described by Kerr et al (7). The 
authors concluded also that adult hippocampal granule neurons 
require circulating adrenal hormones for survival. This finding 
puts forward another important question: do mature neurons 
require survival signals to maintain their viability? Since cell 
death during aging, neurodegenerative disease or injury could 
result from disturbances of the same cell-to-cell interactions in 
vogue during development it is important to know how trophic 
requirements change throughout aging. As shown by Sloviter 
et al (70), it appears that with limited exceptions developing 
neurons express an age-dependent decline in trophic signal 
dependence (11). 
 
DRUG-INDUCED APOPTOTIC NEURODEGENERATION 
Potential of NMDA antagonists as inducers of 
apoptotic neurodegeneration during development
As glutamate promotes certain aspects of neuronal develop-
ment such as migration, differentiation, survival and plasticity, 
evidence that even transient inactivation of NMDA glutamate 
receptors can be lethal has been provided. In 1999 Ikonomi-
dou and colleagues reported that during a specific stage in 
ontogenetic development (between E21 and P14) coinciding 
with the period of NMDA receptor hypersensitivity, transient 
blockade of NMDA receptors with MK801 triggers a huge 
wave of apoptotic neurodegeneration in the cortex and brain-
stem (almost 40 fold in laterodorsal thalamus at P7)(22). In 
addition, phencyclidine and ketamine (NMDA antagonists) 
were also shown to be capable of triggering a robust neurode-
generative response (22). Non-NMDA antagonists, antagonists 
to the cholinergic muscarinic receptors and dopamine receptor 
antagonists failed to do so. Distinct patterns of neurodegene-
ration were observed at different developmental ages which 
suggested that the time window of vulnerability to the apopto-
sis-inducing action of NMDA antagonists coincides with the 
period of synaptogenesis, also known as the brain growth spurt 
period. In the human it spans the last three months of pregnan-
cy and lasts until the first several years of postnatal life (71). 
These studies also suggested that as different combinations of 
neuronal groups become susceptible to apoptotic cell demise 
depending on the period of NMDA receptor deprivation, this 
neurodegenerative mechanism has the potential to induce a 
variety of neurobehavioral disturbances in later life.
Potential of GABA mimetics as inducers of apoptotic 
neurodegeneration during development
The fact that blockade of NMDA receptors during synaptoge-
nesis was capable of inducing a substantial apoptotic neurodege-
neration raised the intriguing question of whether interference 
in other transmitter systems during the same period might also 
trigger apoptotic cell death in the CNS. To explore this possibi-
lity Ikonomidou et al (72) administered numerous agents that 
interact selectively with various transmitter receptor systems 
in the in vivo developing rodent brain. They were able to show 
that only agents that mimic or potentiate the action of GABA 
or GABA-A receptors (benzodiazepines and barbiturates) such 
as phenobarbital, pentobarbital, diazepam and clonazepam, all 
in a dose-dependent manner, triggered widespread cell death 
in the infant rat brain which by various analyses including 
ultrastructural, was apoptotic. NMDA antagonists and GABA 
mimetic drugs both reduced neuronal activity. The authors 
also tested drugs that block sodium channels thereby reducing 
sustained repetitive neuronal firing and found that valproate 
and phenytoin were capable of triggering widespread apoptosis 
in the infant rodent brain (72,73).
Antiepileptic drugs and apoptotic neurodegeneration
Some of the drugs that were shown to cause massive apoptotic 
cell death in the developing brain are currently used in large 
doses as anticonvulsants for pregnant mothers and infants that 
suffer from seizures. Epilepsy is the most common neurological 
disorder of youth and antiepileptic drugs are excessively 
used worldwide as a treatment of choice. Unfortunately, they 
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have been reported to cause cognitive impairment (74-76), 
microcephaly (77-79) and other birth defects. The cause of 
these side effects of therapy with these drugs is unknown. 
Because depression of synaptic transmission is the common 
denominator in the action of antiepileptic drugs Bittigau et 
al (80) postulated that drugs currently used to prevent or 
interrupt seizures such as phenytoin, valproate, phenobarbital, 
pentobarbital, diazepam, clonazepam and vigabatrin may 
stimulate apoptotic cell death during the brain growth spurt. 
Indeed, the results showed that at plasma concentrations 
relevant for seizure control in humans, each drug induced 
wide-spread apoptotic neurodegeneration in the rat brain 
which in some regions such as the thalamus reached up to 
33-fold increase compared to vehicle controls (80). In addition, 
these drugs caused decrease in brain weight. Interestingly, 
combinations of antiepileptic drugs (eg. phenobarbital and 
diazepam) caused more pronounced neurotoxic effect. 
This finding is especially valuable as it offers one possible 
explanation for the increased risk for cognitive impairment 
associated with drug polytherapy. Another important finding 
in these studies was the ability of antiepileptic drugs to depress 
endogenous neuroprotective systems such as BDNF and NT-
3. Neuronal death was associated with reduced expression 
of neurotrophins and decreased concentrations of survival-
promoting proteins. Beta-estradiol, which stimulates pathways 
that are activated by neurotrophins, ameliorated this apoptotic 
neurodegeneration. Estrogen injected in vivo also diminished 
the detrimental effects of phenobarbital and phenytoin. These 
findings present one possible mechanism to explain cognitive 
impairment and reduced brain mass associated with prenatal 
or postnatal exposure of humans to antiepileptic therapy. They 
also imply that measures that promote neurotrophin signaling 
and β-estradiol replacement may offer a novel adjunctive 
neuroprotective approach in the prophylaxis of antiepileptic 
drug-related brain defects.
Potential of common anesthetics as inducers of 
widespread apoptotic neurodegeneration in the 
developing brain
Anesthetics currently used in pediatric surgery act by two 
principal mechanisms: an increase in inhibition via GABA-A 
receptors (benzodiazepines, barbiturates, propofol, isofurane, 
halotane)(81) and a decrease in excitation through NMDA 
receptors (ketamine, nitrous oxide, xenon)(82). As it was 
shown that such agents, applied during a vulnerable period 
of brain synaptogenesis may induce a widespread apoptotic 
neurodegeneration, Jevtovic-Todorovic et al (83) addressed the 
potential risk in the developing brain by administering the most 
commonly used anesthetic cocktails in pediatric anesthesia to 
7 day old infant rats. They found that anesthetic drugs either 
alone, but most impressively in combination (midazolam, 
nitrous oxide and isofurane), in doses sufficient to maintain 
a surgical plane of anesthesia for several hours, caused wide-
spread apoptotic cell death, deficits in hippocampal synaptic 
function, and persistent memory and learning impairment.
Potential of ethanol to induce apoptotic 
neurodegeneration in the developing brain
Ethanol has NMDA antagonist properties and is also a posi-
tive modulator of GABA-A receptors (84-86). This evidence 
prompted the evaluation of the ability of ethanol to mimic 
the proapoptotic effects of NMDA antagonists and GABA 
mimetics. As postulated, ethanol administration in rats and 
mice during the first and second postnatal weeks leads to an 
even more robust response than that triggered by NMDA 
antagonists or GABA mimetics alone (17,72). It also showed 
a substantial decrease in cingulate cortical mass and corpus 
callosum size (17). Electron microscopy revealed that etha-
nol-induced degenerative response conforms to the criteria of 
apoptotic cell death developed by Kerr et al (7) and Ishimaru 
et al (49). In fact, the ability of ethanol to trigger a massive 
wave of apoptosis in the developing mammalian brain pro-
vided the opportunity to study the in vivo apoptotic degene-
ration in fine detail not only in the cortex, but also in the brain 
stem, cerebellum and spinal cord (16,88). It also enabled us 
to compare our ultrastructural findings with those described 
by others in neuronal regions such as sympathetic and dorsal 
root ganglia, hippocampus, and granule cells in the cerebellum 
(9,15,16,70,89). The electron microscopic evidence provided 
by these sources under experimental conditions that were quite 
different from ours, revealed remarkable similarities to the se-
quence and types of changes described by us. A comparison of 
the pattern of neurodegeneration induced by alcohol with that 
induced by NMDA antagonists or GABA mimetics revealed 
that the ethanol pattern comprised a composite of the NMDA 
antagonist and GABA mimetic patterns (17,23). Moreover, 
within the brain growth spurt period different neuronal popu-
lations became sensitive at different times to the mechanism 
by which ethanol triggers apoptotic degeneration. 
The ethanol findings are of particular interest in that exposure 
of the human fetus to ethanol causes a dysmorphogenic 
neurological syndrome known largely as Fetal Alcohol 
Syndrome (FAS), Fetal Alcohol Effects (FAE)(90,91) or Fetal 
Alcohol Spectrum Disorders (FASD)(92). Alcohol Related 
Neurodevelomental Disorder (ARND) is a term recently 
recommended to describe partial syndromes not fully developed 
as FAS (93). The most disabling features of FAS/FAE/FASD 
are neurobehavioral disturbances, learning disabilities, depres-
sion and psychosis (23). While other mechanisms may also 
play a role, the fact that ethanol may cause a widespread and 
large-scale apoptotic neurodegeneration throughout the entire 
neuraxis during the synaptogenesis period, provides a more 
likely explanation than has been available so far for the reduced 
brain mass and major neurobehavioral disturbances associated 
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with FASD (17). 
APOPTOSIS IN NEURODEGENERATIVE DISEASES
It is perhaps natural to expect that the nervous system’s abi-
lity to conduct graceful and orderly removal of cells during 
development might reemerge during injury or the onset and 
progression of certain neurodegenerative diseases. Despite the 
fact that in the recent neuroscience literature, it is increasingly 
being suggested that an apoptotic mechanism may underline a 
wide variety of disease processes affecting the human central 
and peripheral nervous systems (11,13,21,24,94-96), to date 
the role of apoptotic cell death in neurodegenerative disorders 
still remains controversial. Concluding evidence supporting 
the involvement of apoptosis in the pathogenesis of any of the 
chronic neurodegenerative diseases is less than compelling. 
Many agree that there are several important reasons for this 
state of affairs:
1. Contrary to animal studies, it has been a particular 
problem for human studies that almost all brain tissues are 
obtained postmortem and are thus harvested late in the course 
of the disease. Persons dying late in the course of their illness 
have a large scale of perimortem morbidity and various 
uncontrolled factors such as hypoxia, dehydration, sepsis, 
etc, may affect the results of a postmortem examination 
especially by pathomorphological methods. Additionally, 
in a recent review on apoptosis in Alzheimer’s disease Roth 
(13) suggested that “considering the relatively brief period 
during which a cell appears apoptotic and the chronicity of the 
neurodegenerative disease, the number of apoptotic neurons 
in AD brain at any given time may be quite low”.
2. Another problem is still the lack of validated methods 
or agreed upon criteria for identifying neuronal apoptosis and 
distinguishing this cell death process from myriad of others that 
occur in the in vivo mammalian brain. The term “apoptosis” as 
introduced by Kerr and colleagues in the early 70s (7) refers 
to a cell death process that exhibits specific morphological 
ultrastructural features. On the basis of these features it was 
hypothesized that all cell death processes can be placed in 
two categories - apoptosis and necrosis. However, based on 
similar strict morphological and ultrastructural criteria, Olney 
and colleagues have shown that excitotoxic cell death does not 
conform to the Kerr and Wyllie criteria for either of these two 
cell death processes. Other scientists have described excito-
toxic cell death as a necrotic process, as an apoptotic process 
or as a hybrid mixture of the two. It has not yet been clarified 
(at least in the nervous system) how these phenomena match 
the ultrastructural description given by the original coiners of 
the term apoptosis. To add to the existing confusion, various 
other terms such as “excitotoxic apoptosis” or “pathological 
apoptosis” have been introduced. 
3. It is only recently that molecular genetics, molecular 
biology and physiology have started to provide more reliable 
complex criteria for diagnosing apoptosis. For example, it is 
now recognized that the TUNEL staining is not specific for 
apoptosis; it labels also cells that are degenerating by non-
apoptotic mechanism (13,49,87). However, until the mid-90ies, 
the majority of studies in this field heavily relied on TUNEL 
staining and DNA-laddering and only few have applied 
ultrastructural morphological methods.
4. Much of the research pertaining to CNS apoptosis 
has been conducted in cell cultures and despite the wealth 
of information that they have provided especially on the 
mechanisms of apoptotic cell death, these studies are of 
uncertain relevance to the in vivo adult disease process. 
5. In each particular disease model of substantial neuronal 
or glial cell loss that leads to clinically expressed neuro-
degenerative syndrome, it is strategically important to ask 
whether the timing and the number of cells that are involved 
in each particular model is sufficient to consider apoptosis a 
key element of a disease process. 
 Eight years ago in this journal, Timmers and Kremer (95), 
while discussing the controversies linked to the role of apop-
tosis concluded, that “absence of proof is not proof of absence”. 
Probably we still navigate in similar territories. However, 
our knowledge has vastly improved and new evidence for 
the involvement of apoptotic cell death in neurodegenerative 
diseases has generated renewed attention and is widely 
discussed in the literature.
Potential for apoptosis in amyotrophic lateral 
sclerosis
ALS or Lou Gehrig’s disease represents a neurodegenerative 
disorder accompanied by a progressive loss of upper and lower 
motor neurons. It results in a severe disability, progressive 
paralysis and death. The discovery of superoxide dismutase 
(SOD) mutations as a cause for some cases of familial ALS 
(97,98) has supported a role of apoptosis since the effect of the 
mutation is to convert an antioxidant defense enzyme into a 
proapoptotic compound (21,24,99). Transgenic mice have been 
generated expressing different mSOD1 genes identified in ALS 
patients (100). Like humans with ALS, these mice develop 
an adult-onset progressive motor deterioration (101,102). 
Although the mechanism leading to motor neuron loss are 
not thoroughly understood it has been proposed that caspases 
-1 and -3 play an instrumental role in the neurodegeneration 
process (103,104) suggesting that caspase inhibition may have 
a therapeutic role. 
Potential for apoptosis in Parkinson’s disease (PD).
Apoptosis and oxidative stress have been implicated in the 
progressive loss of dopaminergic neurons of substantia nigra 
in PD (24,105-107). Data from two postmortem studies have 
shown contradicting results. Marshal et al (108) reported that 
Bcl-2 is significantly raised in the basal ganglia regions of PD 
patients as compared to age-matched controls. A similar trend 
was also found in Lewy Body disease and proposed that Bcl-
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2 increases in some brain regions as an early event and that 
these brain regions are under a stress for many years before 
any symptomatic changes occur. On the other hand, Vyas et al 
(109) reported that the expression of Bcl-2 protein by Western 
blot analysis and immunohistochemistry was unaltered in the 
nucleus basalis of Meynert and substantia nigra. However, the 
same group provided morphological evidence for apoptosis 
in melanized neurons of the substantia nigra in PD patients 
(110). Mogi et al (111) reported that the soluble form of Fas 
molecule is elevated in the tissues homogenates from nigro-
striatal dopaminergic regions of PD brains. 
Potential for apoptosis in Alzheimer’s disease (AD)
Do neuronal cells degenerate via apoptotic or non-apoptotic 
pathway in AD patients? Extensive neuronal loss occurs in AD 
brains and some authors have speculated that deregulation of 
apoptotic death pathways is etiologically responsible for the 
disease development (see ref. 13 for an extensive review). It 
has been suggested that apoptosis operates as a mechanism 
of cell death for at least some neurons in AD and that this 
process may not be restricted to neurons, but may also occur 
in microglia (112). Lack of morphologically convincing apop-
totic neurons in the vast majority of AD brains has led to the 
revised hypothesis that apoptosis-associated molecular events 
cause neuronal dysfunction in the absence of, or prior to, neu-
ronal death (13). Proof of apoptotic cell death mechanism in 
AD brain tissue has been based mainly on the demonstration 
of TUNEL-positive staining (113,114) and DNA laddering 
and only lately on correlations with apoptotic markers such 
as Bcl-2, Bax, c-Jun, Fos (24,112). Activated caspase-3 im-
munoreactivity has been reported only in single hippocampal 
neurons undergoing granulovacuolar degeneration but not in 
senile plaques or neurofibrillary tangles. (13,115). Based on 
this and evidence from AD mouse models, it was suggested 
that activated caspase-3 does not appear to have a significant 
role in the widespread neuronal cell death that occurs in AD, 
but may contribute to the specific loss of hippocampal neurons 
involved in learning and memory. Ultrastructural evidence 
has been even less compelling as much of the information 
on cell death in AD has been gathered from the endpoints 
of the disease process when various other factors may have 
intervened, most notably the process of dying. To overcome 
this, over the past decade it has been of crucial importance for 
neuroscientists to model the beginning of AD pathology and, 
particularly, the subclinical pathology that exists in patients 
at an early age. The way to circumvent this problem has been 
the creation of in vitro and in vivo models of AD pathology in 
animals and human-derived tissue. At least 7 different caspases 
(including caspases -3, -8 and -9) have been implicated in 
regulating neuronal cell death in response to amyloid-beta 
exposure in vitro, in animal models of neurodegenerative 
diseases, and in AD brain. The data from such studies 
have not been encouraging despite the impressive flood of 
information implicating caspases and apoptosis as contributing 
etiologic factors. For example, although it has been suggested 
that presenilin genes and amyloid precursor protein (APP) 
mutations may be involved in the apoptotic process (116), 
amyloid-beta deposition in the APP transgenic mouse model 
of AD did not result in caspase-3 activation despite the ability 
of amyloid-beta to induce caspase-3 activation and neuronal 
apoptosis in vitro (115). There is little evidence to date for 
the involvement of an apoptotic neurodegenerative process in 
genetic animal models based on similar mutations (24,117). 
Thus the direct involvement of caspase-dependent neuronal 
apoptosis in AD pathogenesis is still uncertain. On the other 
hand, based on evidence stemming from culture experiments, 
neuronal apoptosis might be induced by a variety of stimuli and 
many of these conditions are known to be present in the AD 
brain. For example, application of amyloid-beta has resulted 
in apoptosis-like morphology (118,119) and the induction of 
immediate early gene proteins (120). Other potential inducers 
of apoptotic neuronal death include oxidative insults and 
damage, sensitizing the cell to trophic factor deficiency, 
altering APP metabolism, protein trafficking and G-protein 
related mechanisms (see also 24,113). However there is 
yet no firm evidence to support apoptotic cell death with 
APOE allele 4 (associated with a high risk for AD) although 
in vitro evidence suggests that APOE and APP can interact 
to produce increased oxidative damage to neurons (121). 
Despite these discouraging and controversial developments 
in AD apoptology, Roth (13) suggested the possibility that 
apoptotic neuronal death may contribute to neuronal loss only 
in a tertiary fashion. He speculated that there is a sub-lethal 
increase in pro-apoptotic molecules and if pro-death stimuli 
persist, cell death will ultimately occur and “caspases may be 
involved in the last stage of the disease process”. If so, caspase 
inhibition offers some hope for extending neuron survival so 
that other agents, targeting upstream events, may delay or 
possibly reverse AD pathology. 
Potential for apoptosis in spinal muscular atrophy 
(SMA)
In this severe human disorder PCD that occurs in spinal 
motoneurons during normal development continues unabated 
in SMA patients resulting in massive motoneuron death and 
subsequent respiratory failure. SMA or Werdig-Hoffmann 
disease as it is otherwise known is probably the most severe 
form in the human neurodegenerative disease family. It leads 
almost certainly to death by the age of three. In approximately 
70% of young infants the first two coding exons of the gene 
for the neuronal apoptosis inhibitory protein (NAIP) at 
chromosome 5 are deleted (11,24,122). This implies that failure 
to inhibit PCD because of genetic deficits at an appropriate 
time during development may be responsible for the massive 
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cell loss as seen in SMA patients. It shows also that absence of 
apoptotic cell death in the mature nervous system is likewise 
dependent on active genetic mechanisms that are anti-apoptotic 
in nature. 
Potential for apoptosis in Battens’s disease
The most convincing case for an involvement of apoptosis 
in human disease reported so far pertains to Battens disease, 
also termed neuronal ceroid lipofuscinosis (24). The disease 
is characterized by massive neuronal cell death and, in most 
cases, death of photoreceptors in the retina with a resultant 
blindness. Recent studies have shown that cell deletion is 
accompanied by elevation of Bcl-2 and ceramide levels, 
implicating a close relationship to the regulation of apoptotic 
cell death process. The discovery of the responsible gene 
CLN3 on chromosome 16 shows that a product of this gene, 
a 438-aminoacid protein is operative in a novel antiapoptotic 
pathway. The human disease is associated with deletions of the 
CLN3 gene, which apparently results in loss of function.
CONCLUSION
The last case in the present review illustrates the sheer 
power of characterizing the precise molecular mechanisms 
that control the survival of neurons during development and 
disease. PCD is regulated by key molecular mechanisms that 
initiate and execute cell death. PCD and induced apoptotic 
neuronal cell death share common molecular steps. The 
recent characterization of such mechanisms has resulted in 
the identification of various molecules that may arrest disease-
related cell loss. A deeper understanding of these processes 
may lead to the discovery of multiple strategies for slowing, 
reducing or even arresting neuronal and glial cell death induced 
by injury, aging or disease.
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